Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Pharmaceuticals Regulatory News (HEMO)

Share Price Information for Hemogenyx Pharmaceuticals (HEMO)

Share Price is delayed by 15 minutes
Get Live Data
724.00    -5.50 (-0.75%)
Bid:
725.00
Ask:
747.00
Spread: 22.00 (3.034%)
Market Cap: £49.23m
HEMO Live PriceLast checked at - London Stock Exchange

Intraday Hemogenyx Pharmaceuticals Share Chart

Statement re possible acquisition

30 Dec 2015 07:00

RNS Number : 3726K
Silver Falcon PLC
30 December 2015
 

30 December 2015

SILVER FALCON PLC

("Silver Falcon" or the "Company")

 

Proposed acquisition of Lime Holdings Limited ("Lime")

 

Silver Falcon plc (LSE:SILF), the listed special purpose acquisition company, refers to its announcement of 23 December 2015 and is pleased to advise that it has entered into a non-binding Memorandum of Understanding with the board and principal shareholder in Lime Holdings Limited ("Lime") regarding a possible acquisition of 100% of the share capital of Lime by way of a share for share exchange ("Transaction").

Lime is an Australian unlisted public company which operates in the financial technology sector. It has developed an innovative platform for the insurance industry which facilitates the automated delivery of insurance to end users.

Lime has recently relocated its headquarters to the UK and is developing commercial partnerships in the UK and on an international basis.

Whilst a general understanding on the terms of the Transaction has been reached, these terms are subject to due diligence, a fundraising, and re-listing of the enlarged group on the London Stock Exchange. Accordingly there is no certainty that it will be completed.

If the Transaction is completed, it will constitute a reverse takeover under the Listing Rules. As the Company is unable to provide full disclosure under Rule 5.6.15 of the Listing Rules, the Company has requested a continuation of the current suspension of trading in its shares.

Further announcements will be made in due course as the Transaction progresses.

 

For further information please contact:

Silver Falcon: Tim Le Druillenec (Company Secretary), 07874 762821

Media enquiries: Jennifer Renwick, jennifer.renwick@camarco.co.uk, 0203 757 4994

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQTLBPTMBTTBAA
Date   Source Headline
29th May 20269:18 amRNSGrant of Options and Extension of Warrant Term
30th Apr 20264:04 pmRNSFinal Results
28th Apr 20267:00 amRNSInstitutional Fundraise
14th Apr 20267:00 amRNSAnnual IND Report with FDA
31st Mar 20261:22 pmRNSTech Transfer Completion and Clinical Trial Update
27th Feb 20268:10 amRNSTotal Voting Rights
24th Feb 20267:00 amRNSHolding(s) in Company
23rd Feb 20267:00 amRNSExercise of Warrants and Issue of Equity
10th Feb 20263:52 pmRNSIssue of Equity - Correction
10th Feb 20267:00 amRNSIssue of Equity
30th Jan 20267:00 amRNSTotal Voting Rights
12th Jan 20267:00 amRNSHolding(s) in Company
22nd Dec 20258:00 amRNSUpdate on Admission of Shares
18th Dec 20257:00 amRNSIssue of Equity
8th Dec 202512:48 pmRNSHolding(s) in Company
28th Nov 20257:00 amRNSTotal Voting Rights
19th Nov 202511:47 amRNSPublication of Prospectus
29th Oct 20257:00 amRNSClinical Trial Update and Grant of Share Awards
6th Oct 20257:00 amRNSClearance to Initiate Pediatric Enrolment
30th Sep 20257:00 amRNSHalf-year Report
30th Sep 20257:00 amRNSTotal Voting Rights
23rd Sep 20257:00 amRNSHemogenyx Signs Letter of Intent
18th Sep 20251:16 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSThird Patient Safety
11th Sep 20257:00 amRNS-RInvitation to Participate at DCNY Summit
8th Sep 20257:00 amRNSManufacturing Partnership with Made Scientific
5th Sep 20257:00 amRNSExercise of Warrants and Issue of Equity
3rd Sep 20251:57 pmRNSExercise of Warrants and Issue of Equity
1st Sep 20253:06 pmRNSIssue of convertible loan notes
29th Aug 20257:00 amRNSResult of Audit Tender
26th Aug 202511:44 amRNSHemogenyx raises £570,000 and Director's Dealing
15th Aug 20257:00 amRNSThird Patient Treated with HG-CT-1 CAR-T Therapy
31st Jul 20257:00 amRNSTotal Voting Rights
29th Jul 20258:00 amRNSPlacing to Raise £250,000 and Director’s Dealing
16th Jul 20257:00 amRNSHemogenyx Awarded Grant
30th Jun 20257:00 amRNSTotal Voting Rights
17th Jun 20257:00 amRNSClearance to Proceed with Pediatric Expansion
3rd Jun 20252:02 pmRNSPlacing to Raise £451,250 and Director’s Dealing
3rd Jun 20257:00 amRNSSecond Patient Passes Initial Safety Tests
30th May 20253:14 pmRNSTotal Voting Rights
29th May 20252:06 pmRNSResult of AGM
14th May 20257:00 amRNS-RPediatric Amendment to Clinical Protocol
13th May 20257:00 amRNSAGM Correction
8th May 20257:00 amRNSPlacing to Raise £451,250 and Director’s Dealing
2nd May 20254:24 pmRNSNotice of AGM
2nd May 20257:00 amRNSSecond Patient Treated with HG-CT-1 CAR-T Therapy
28th Apr 20257:00 amRNSFinal Results
3rd Apr 20257:00 amRNS-RFDA Annual Report
31st Mar 20257:00 amRNSTotal Voting Rights
24th Mar 20257:00 amRNSFirst Patient Safety

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.